Stock GLAND GLAND PHARMA LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

News Gland Pharma Limited Bombay S.E.

Equities

GLAND

INE068V01023

Market Closed - Bombay S.E.
Other stock markets
 03:30:48 29/04/2024 pm IST 		5-day change 1st Jan Change
1,728 INR -0.06% Intraday chart for Gland Pharma Limited -2.77% -10.17%
10:43am Gland Pharma Names COO MT
07:25am Gland Pharma Gets US FDA's Final Approval for Generic Drug for Luteinizing Hormone Surges MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Gland Pharma Names COO
MT
Gland Pharma Gets US FDA's Final Approval for Generic Drug for Luteinizing Hormone Surges
MT
Nicomac Machinery and RP Advisory Services Reportedly Likely to Sell 4.4% Stake in Gland Pharma via Block Deals
CI
Gland Pharma Gets US FDA Approval for Eribulin Mesylate Injection
MT
Gland Pharma Limited Receives Approval from the United States Food and Drug Administration for Eribulin Mesylate Injection 0.5 Mg/ML Single Dose Vial
CI
Gland Pharma COO, Chief Technical Officer Step Down
MT
Gland Pharma Limited Announces Change in Management
CI
Gland Pharma Names New President of Phixen Subsidiary
MT
Jefferies Adjusts Gland Pharma’s Price Target to INR2,400 From INR2,250, Keeps at Buy
MT
Gland Pharma's Consolidated Profit Drops in Fiscal Q3
MT
Transcript : Gland Pharma Limited, Q3 2024 Earnings Call, Feb 14, 2024
Gland Pharma Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023
CI
Indian shares set to open lower as hot US inflation spurs rate worries
RE
Gland Pharma Gets Establishment Inspection Report from US FDA for Pashamylaram Unit
MT
32,656,565 Equity Shares of Gland Pharma Limited are subject to a Lock-Up Agreement Ending on 18-NOV-2023.
CI
Gland Pharma Gets US FDA's Tentative Approval for Generic Hypotension Drug
MT
Gland Pharma Limited Receives Tentative Approval for Angiotensin II Injection
CI
Abbott India's Q2 profit climbs on strong sales
RE
Nomura Upgrades Gland Pharma to Neutral From Reduce, Adjusts Price Target to INR1,570 From INR1,157
MT
Gland Pharma Gets US FDA's EIR Report Closing Inspection of Visakhapatnam, India Unit
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. GLAND Stock
  4. GLAND Stock
  5. News Gland Pharma Limited